Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study.
- DOI
- 10.1177/17562848261487334
- Published
- 2026
- Container
- Therapeutic advances in gastroenterology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1177/17562848261487334,
title = {Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study.},
author = {Levartovsky A and Lukáš M and Abitbol CM and Vlková K and Ben-Horin S and Lukáš M and Kopylov U},
year = {2026},
journal = {Therapeutic advances in gastroenterology},
doi = {10.1177/17562848261487334},
url = {https://doi.org/10.1177/17562848261487334}
}RIS
TY - JOUR TI - Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study. AU - Levartovsky A AU - Lukáš M AU - Abitbol CM AU - Vlková K AU - Ben-Horin S AU - Lukáš M AU - Kopylov U PY - 2026 JO - Therapeutic advances in gastroenterology DO - 10.1177/17562848261487334 UR - https://doi.org/10.1177/17562848261487334 ER -
APA
A, L., M, L., CM, A., K, V., S, B., M, L., & U, K. (2026). Long-term real-world effectiveness and safety of mirikizumab in ulcerative colitis: 52-Week results from an expanded international two-center retrospective cohort study.. Therapeutic advances in gastroenterology. https://doi.org/10.1177/17562848261487334
Source records
- pubmed · retrieved 2026-09-25T08:54:20.406Z